KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 156 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 4.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $51,565 | -57.4% | 28,807 | -7.3% | 0.00% | -100.0% |
Q1 2023 | $120,940 | +75.5% | 31,090 | +53.4% | 0.00% | 0.0% |
Q4 2022 | $68,908 | -35.0% | 20,267 | +4.3% | 0.00% | 0.0% |
Q3 2022 | $106,000 | +27.7% | 19,423 | +5.1% | 0.00% | 0.0% |
Q2 2022 | $83,000 | -38.5% | 18,474 | +0.5% | 0.00% | 0.0% |
Q1 2022 | $135,000 | +14.4% | 18,379 | +0.5% | 0.00% | 0.0% |
Q4 2021 | $118,000 | +24.2% | 18,288 | +11.8% | 0.00% | 0.0% |
Q3 2021 | $95,000 | -43.1% | 16,364 | +0.8% | 0.00% | 0.0% |
Q2 2021 | $167,000 | +5.7% | 16,230 | +8.2% | 0.00% | 0.0% |
Q1 2021 | $158,000 | -31.6% | 14,998 | +0.5% | 0.00% | -50.0% |
Q4 2020 | $231,000 | +2.7% | 14,916 | -3.4% | 0.00% | 0.0% |
Q3 2020 | $225,000 | +14.8% | 15,444 | +49.1% | 0.00% | -33.3% |
Q2 2020 | $196,000 | -13.7% | 10,356 | -12.2% | 0.00% | -25.0% |
Q1 2020 | $227,000 | – | 11,793 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |